PACB•benzinga•
Piper Sandler Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.25
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 15, 2025 by benzinga